418P Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC): 5-year update of the phase III CAPSTONE-1 study

In the phase III CAPSTONE-1 trial, addition of adebrelimab, a humanized IgG4 anti–PD-L1 monoclonal antibody, to chemotherapy (chemo) significantly improved overall survival (OS) as first-line treatment for ES-SCLC at the primary analysis (data cutoff [DCO], Oct 8, 2021), supporting approval of the regimen for this indication in China in 2023. Here, we report updated outcomes 5 yrs after enrollment of the last patient.